Novaliq GmbH, founded in 2007, is a specialty pharmaceutical company focused on the development of innovative water-free ophthalmics and located in the Heidelberg Technology Park, Germany.
Our mission is to transform Active Pharmaceutical Ingredients (APIs) into highly effective ocular therapeutics for both the front and the back of the eye.
NovaTears®, a first-in-class, water-free product with a novel mode of action for treatment of evaporative dry eye is registered and marketed in Europe.
The most advanced Rx development is CyclASol® for the treatment of moderate to severe dry eye disease. Recent reported phase 2 data confirmed that CyclASol® has demonstrated a superior outcome and an earlier onset of action when compared head to head vs. Restasis™.
All product developments are based on Novaliq’s proprietary drug delivery technology called EyeSol® which enhances the topical bio-availability, stability and safety of traditionally unstable APIs improving the delivery, efficacy and convenience of treatments for ocular surface diseases, including dry eye, through preservative free and multi dose formulations.